Efficacy of stem cell therapy for pulmonary arterial hypertension: a systematic review and meta-analysis of preclinical studies

Ding, Xian-Fei; Liang, Huo-Yan; Yuan, Bo; Li, Li-Feng; Wang, Tian; Kan, Quan-Cheng; Wang, Le-Xin; Sun, Tong-Wen

doi:10.1186/s13287-019-1162-8

Stem Cell Research & Therapy

Table 1 General characteristics of preclinical studies investigating the efficacy of stem cells in models of PAH

From: Efficacy of stem cell therapy for pulmonary arterial hypertension: a systematic review and meta-analysis of preclinical studies

Author (year)	Species, strain, sex	No. of controls	No. of treated animals	PAH model	SC source	SC route	SC dose	Timing of SC therapy after PAH	Follow-up (weeks)
Lim et al.(2016) [39]	Rat, SPF, M	5	5	MCT (60 mg/kg)	hBM	Tail vein	2.5 × 10⁵	14 days	2 weeks
Lee et al. (2017) [36]	Rat, SPD, M	4	6	MCT (60 mg/kg)	hUCB	Jugular vein	3 × 10⁵	7 days	1 week
		4	6						3 weeks
		4	6						3 weeks
		4	4				3 × 10⁵	7 days	1 week
		4	4						3 weeks
		4	4						3 weeks
Guo et al. (2013) [30]	Rat, SPD, M	10	10	MCT (60 mg/kg)	rBM	Jugular vein	5 × 10⁶	21 days	3 weeks
Luan et al.(2012) [42]	Rat, SPD, NR	20	20	Surgical operation	rBM	Sublingual vein	1–5 × 10⁶	28 days	2 weeks
Baber et al. (2006) [25]	Rat, SPD, M	10	10	MCT (60 mg/kg)	rBM	Intratracheal	3 × 10⁶	14 days	3 weeks
Chen et al. (2014) [27]	Rat, SPD, NR	7	7	MCT (50 mg/kg)	rBM	Intravenous	5 × 10⁶	21 days	2 weeks
Chen et al. (2016) [26]	Rat, Wistar, M	10	10	MCT (60 mg/kg)	rBM	Tail vein	1 × 10⁶	14 days	3 weeks
Cheng et al. (2017) [29]	Rat, Lewis, M	10	10	MCT (60 mg/kg)	rBM	Tail vein	3 × 10⁶	21 days	3 weeks
Huang et al.(2016) [31]	Rat, SPD, M	6	6	MCT (60 mg/kg)	iP	Tail vein	2 × 10⁶	14 days	4 weeks
Chen et al.(2016) [28]	Rat, SPD, M	8	8	MCT (60 mg/kg)	hUCB	Caudal vein	1 × 10⁶	5 days	3 weeks
Jiang et al.(2012) [32]	Rat, SPD, NR	8	43	MCT (60 mg/kg)	rBM	Tail vein	4 × 10⁶	3 days	3 weeks
Kang et al. (2015) [33]	Rat, SPF, M	10	10	MCT (60 mg/kg)	hUCB	Tail vein	2.5 × 10⁵	14 days	2 weeks
Kimet al (2012) [34]	Rat, SPD, M	6	6	MCT (60 mg/kg)	rBM	Tail vein	2 × 10⁷	7 days	1 week
Kimet al (2012) [34]	Rat, SPD, M	6	6	MCT (60 mg/kg)	rBM	Tail vein	2 × 10⁷	7 days	3 weeks
Kim et al. (2016) [35]	Rat, SPD, M	6	6	MCT (60 mg/kg)	hUCB	External jugular vein	3 × 10⁶	7 days	1 week
		6	6						3 weeks
		6	6
		8	8
Liang et al. (2015) [38]	Rat, SPD, M	10	10	MCT (40 mg/kg)	rADM	Left external jugular vein	1 × 10⁶	7 days	2 weeks
Liang et al. (2015) [38]	Rat, SPD, M	8	10	MCT (40 mg/kg)	rADM	Left external jugular vein	1 × 10⁶	7 days	3 weeks
Liu et al. (2015) [40]	Rat, SPD, F	8	8	MCT (60 mg/kg)	hUCB	Caudal vein	1 × 10⁶	5 days	3 weeks
Luan et al. (2013) [43]	Rat, SPD, M	10	10	MCT (50 mg/kg)	rBM	Sublingual vein	1 × 10⁷	7 days	23 weeks
Luo et al. (2014) [44]	Rat, SPD, M	8	8	MCT (40 mg/kg)	rADM	Left jugular vein	1 × 10⁶	14 days	1 week
		8	8						2 weeks
		8	8						3 weeks
Raoul et al. (2007) [45]	Mouse, C57BL/6, F	5	5	MCT (5 mg/kg)	rBM	Tail vein	2.5 × 10⁶	3 days	3 weeks
Rathinasabapathy et al. (2016) [46]	Rat, SPD, M	8	8	MCT (50 mg/kg)	rADM	Jugular vein	1 × 10⁶	14 days	2 weeks
Somanna et al. (2014) [47]	Rat, SPD, NR	6	6	MCT (60 mg/kg)	hADM	Intratracheal	3 × 10⁶	14 days	2 weeks
Zhang et al. (2012) [49]	Mouse, ICR, NR	10	10	MCT (400 mg/kg)	rBM	Tail vein	5 × 10⁵	7 days	2 weeks
Zhang et al. (2012) [50]	Rat, SPD, M	9	9	MCT (50 mg/kg)	hUCB	Sublingual vein	3 × 10⁶	7 days	2 weeks
Umar et al. (2009) [48]	Rat, Wistar, F	10	10	MCT (60 mg/kg)	rBM	Jugular vein	1 × 10⁶	14 days	2 weeks
		10	10						3 weeks
		10	10						4 weeks
Liu et al. (2011) [41]	Rat, Wistar, M	17	16	Surgical operation	rADM	Right jugular vein	5 × 10⁷	84 days	2 weeks
Takemiya et al. (2009) [15]	Rat, Lewis, M	10	10	MCT (60 mg/kg)	rBM	Tail vein	5 × 10⁵	14 days	2 weeks
Horimoto et al. (2005) [14]	Rat, SPD, M	10	10	MCT (60 mg/kg)	rBM	Right femoral vein	1 × 10⁶	7 days	2 weeks
Lee et al. (2015) [37]	Rat, SPD, M	8	8	MCT (60 mg/kg)	hUCB	External jugular vein	3 × 10⁶	7 days	1 week
		8	8						2 weeks
		8	8						3 weeks

PAH pulmonary arterial hypertension, SPF specific-pathogen-free, SPD Sprague Dawley, M male, F female, NR not reported, SCs stem cells, hBM human bone marrow mesenchymal tissue, hUCB human umbilical cord blood-derived mesenchymal tissue, rBM rat bone marrow mesenchymal tissue, iP murine-induced pluripotent stem cells, BM bone marrow mesenchymal tissue, rADM rat adipose-derived stromal tissue, ADM adipose-derived stromal tissue
Follow-up (weeks) indicates the observation time of outcomes after stem cell administration

Back to article page

ISSN: 1757-6512

Contact us

Submission enquiries: Access here and click Contact Us
General enquiries: info@biomedcentral.com